IBM Watson: How Cognitive Computing Can Be Applied to Big Data Challenges in Life Sciences Research  by Chen, Ying et al.
Clinical Therapeutics/Volume 38, Number 4, 2016
Review ArticleIBM Watson: How Cognitive Computing Can Be
Applied to Big Data Challenges in Life
Sciences ResearchYing Chen, PhD1; Elenee Argentinis JD2; and Griff Weber1
1IBM Almaden Research Center, San Jose, California; and 2IBM Watson, New York, New YorkAccepted for publication March 1, 2016.
http://dx.doi.org/10.1016/j.clinthera.2015.12.001
0149-2918/$ - see front matter
& 2016 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ABSTRACT
Life sciences researchers are under pressure to
innovate faster than ever. Big data offer the promise
of unlocking novel insights and accelerating break-
throughs. Ironically, although more data are available
than ever, only a fraction is being integrated, under-
stood, and analyzed. The challenge lies in harnessing
volumes of data, integrating the data from hundreds
of sources, and understanding their various formats.
New technologies such as cognitive computing offer
promise for addressing this challenge because cogni-
tive solutions are speciﬁcally designed to integrate and
analyze big datasets. Cognitive solutions can under-
stand different types of data such as lab values in a
structured database or the text of a scientiﬁc publica-
tion. Cognitive solutions are trained to understand
technical, industry-speciﬁc content and use advanced
reasoning, predictive modeling, and machine learning
techniques to advance research faster.
Watson, a cognitive computing technology, has been
conﬁgured to support life sciences research. This version
of Watson includes medical literature, patents, genomics,
and chemical and pharmacological data that researchers
would typically use in their work. Watson has also been
developed with speciﬁc comprehension of scientiﬁc
terminology so it can make novel connections in millions
of pages of text. Watson has been applied to a few pilot
studies in the areas of drug target identiﬁcation and drug
repurposing. The pilot results suggest that Watson can
accelerate identiﬁcation of novel drug candidates and
novel drug targets by harnessing the potential of
big data. (Clin Ther. 2016;38:688–701) & 2016 The
Authors. Published by Elsevier HS Journals, Inc.
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medicine.688Basic science, clinical research, and clinical practice
generate big data. From the basic science of genetics,
proteomics, and metabolomics to clinical research and
real-world studies, these data can be used to support
the discovery of novel therapeutics.1,2 This article
reviews a cognitive technology called IBM Watson
and describes early pilot projects. The project out-
comes suggest that Watson can leverage big data in a
manner that speeds insight and accelerates life sciences
discoveries. This commentary is a 5-part discussion of
the following: (1) the need for accelerated discovery,
(2) the data hurdles that impede discovery, (3) the
4 core features of a cognitive computing system and
how they differ from those of previous systems,
(4) pilot projects applying IBM Watson to life sciences
research, and (5) potential applications of cognitive
technologies to other life sciences activities.PART I: SOLUTIONS THAT CAN ANALYZE BIG
DATA ARE NEEDED IN LIFE SCIENCES
RESEARCH
Although debated, recent estimates suggest that the
costs of bringing a new drug to market has reached
$2.5 billion and 412 years of investment.3 Of drug
candidates, 80% to 90% fail to gain U.S. Food and
Drug Administration approval.4 The most common
reasons for failure include lack of efﬁcacy, lack of
safety, poor dosage selection, and poor endpoint
selection.4,5 Looking across disease states, in some
therapeutic areas approval rates are as low as 6.7%.6Volume 38 Number 4
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dles to developing a successful drug candidate. Greater
availability of generic drugs is one of these hurdles.
Generic prescriptions made up 82% of all prescriptions
dispensed in 2014.7 In established therapeutic areas
such as cardiovascular disease, studies have compared
generic drugs to brand-name medications. The study
results indicate that generic drugs are associated with an
8% reduction in cardiovascular outcomes including
hospitalizations for acute coronary syndrome, stroke,
and all-cause mortality versus their brand-name coun-
terparts. These outcome improvements were attributed
to better adherence to generic drugs.8 In type 2 diabetes,
hypertension, and hyperlipidemia there are 4 or more
generic agents available.9 Brand-name medications in
these therapeutic areas come with costs of 8 to 10 times
more than costs of available generics. New agents must
therefore be more effective or safer than existing low-
cost generic options to justify the price differential.
Biopharmaceutical companies have shifted to orphan
(rare) diseases and cancer in which there is a dearth of
medications and regulatory incentives.10 Orphan
diseases also present challenges to the discovery of
new therapeutics including the heterogeneity of
diseases, inadequate understanding of the natural
history of these diseases, and a lack of biomarkers to
aid outcomes studies.11 In both cases, companies need
to speed advances in research. They need to accelerate
breakthroughs in disease pathophysiology, drug target
identiﬁcation, and early candidate evaluation so that
more viable drug candidates can be approved and
provided to patients.
Today’s life sciences researchers have a spectrum of
data available to them. The data come in many
varieties including high-throughput screening, genomic
sequencing, mass spectrometry, metabolomics and
transcriptomic data, phenotyping, and more.12,13 Big
data are important to scientiﬁc discovery because they
hold the potential to unlock the origins of disease and
open up new avenues to prevention and treatment. For
example, gene sequencing, which helps to identify gene
mutations that cause diseases, generates terabytes of
data. This dataset alone is a challenge to maintain in a
sustainable environment while also allowing rapid
analysis of the information. The data quickly become
unmanageable when you add other types of data such
as proteomics and metabolomics. If these datasets
could be combined and connected to other data types,
insights from each dataset could be pieced together toApril 2016unlock understanding about the origins and processes
of many diseases.12 The challenge lies in combining,
interpreting. and analyzing vast and disparate data
types from different sources.12 As a result, the potential
of big data has yet to be fully realized because current
solutions cannot fully contend with its scale and
variety. 12,13 There is a need for technology solutions
that address these issues to enable more productive and
efﬁcient research. Ultimately, the beneﬁt that these
technologies should confer is the accelerated discovery
of viable drug targets, drug candidates, and other novel
treatment modalities.PART II: THE TYPES OF CHALLENGES POSED
BY BIG DATA
Big data come with inherent challenges that include
volume, velocity, variety, and veracity. Each of these
facets should be addressed in the design of a technology
solution. First, a solution must be able to manage the
sheer volume of data available and “keep up” with
integrating new data that are constantly being produced.
There are nearly 200,000 active clinical trials, 21,000
drug components, 1357 unique drugs, 22,000 genes, and
hundreds of thousands of proteins.14,15 Each of these
areas of study includes testing and experiments that yield
vast quantities of data, making it difﬁcult for any 1
researcher or even teams of scientists to absorb.15–17
There are 424 million published medical and scientiﬁc
articles in the 5600 journals in MEDLINE alone, with
1.8 million new articles published annually.18,19 Mean-
while, the average researcher typically reads on average
250 to 300 articles in a given year.20 This suggests that
scientists may not be keeping up with the basic science
published in their area of specialty, let alone making
novel connections that could come from harnessing
many data sources.20,21 The volume of published science
grows at a rate of 9% annually, doubling the volume
of science output nearly every 9 years.22 The ability to
absorb only a fraction of available information results in
many lost opportunities to further research. Drug
discovery depends on identifying novel and effective tar-
geting strategies that produce better clinical outcomes for
patients. Harnessing volumes of information about how
disease processes originate and progress and how drugs
affect animals and humans could yield novel treatment
strategies.
In order to unlock the potential in data, data must
be understood in all its varieties. Structured data689
Clinical Therapeuticsinclude data contained in tables or data cells such as
names, addresses, and isolated lab values. Today, a
high percentage of data is unstructured. Unstructured
data are information such as text where meaning is
often derived from context. Other unstructured data
types include images, X-rays, sonograms, electrocar-
diograms, magnetic resonance images, and mass spec-
trometry results.13
Data variety is often accompanied by the issue of
data silos. For example, with respect to any biophar-
maceutical company’s drug, data from chemical re-
action experiments, high-throughput screening,
animal studies, human trials, and postmarketing drug
safety surveillance are often kept in different reposi-
tories. Data silos exist in most organizations, and
existing approaches to integration and analysis have
not been completely successful in addressing data scale
or diversity. Additionally, there are hundreds of
external data sources covering patents, genes, drug
labels, chemical compounds, proteins, and published
studies. For a solution to successfully address these
challenges, it must be able to support the aggregation
of big data from multiple sources and retain these data
in a stable, secure environment with efﬁcient processes
for integrating new data so that the insights generated
are accurate, current, and relevant.
Another challenge with large datasets is the pres-
ence of data “noise.” The term noisy data refers to
information that is dense, complex, or characterized
by conﬂicting indicators that can make drawing
conﬁdent conclusions from it difﬁcult. Conﬂicting
and “noisy” data are a common issue in most ﬁelds
including life sciences and medicine. This issue is
particularly important in medicine in which
evidence-driven decisions are the foundation for car-
ing for patients. Study veracity, quality, and replica-
bility are often under discussion.20 Resolving
evidentiary conﬂicts or at least surfacing them while
pointing directly to the publication passages would
offer researchers the opportunity to read the source
text and evaluate the information further. Today’s
systems tend to rely on humans to curate (collect and
organize) and evaluate evidence, which presents 2
problems. First, a human may not encounter the
evidence in favor of or against a particular
hypothesis if it is buried in millions of pages of data.
Second, humans tend to approach problems with
some bias. A cognitive system could access more690data and surface any evidence in favor of or against
a hypothesis.
PART III: COGNITIVE TECHNOLOGIES: A NEW
WAY TO AGGREGATE AND UNDERSTAND
BIG DATA
Cognitive technologies are an evolution in computing
that mimics some aspects of human thought processes
on a larger scale. In this case, scale refers to the ability
to process the volumes of data and information
available in the scientiﬁc domain. Technology devel-
opers have realized that human reasoning, learning,
and inference comprise one of the most sophisticated
thinking systems in existence.23–25 Still, human cogni-
tion has limitations, 2 of which include scalability and
bias. Cognitive systems attempt to mimic aspects of
human thinking while adding the ability to handle
large amounts of information and evaluate it
without bias.
In the computing community, the deﬁnition of
cognitive computing is a topic of debate. It is often
associated with artiﬁcial intelligence (AI), a ﬁeld of
technology that covers broad aspects of human
intelligence.26 AI includes the skills related to
reasoning and problem solving but also perception
(face recognition and vision) and the ability to
manipulate objects (robotics).26 In this paper,
cognitive computing refers to a combined subset of
these technologies that read, reason, learn, and make
inferences from vast sets of unstructured content.27
Even in the area of cognition, AI tends to focus on
individual algorithms and models that mimic speciﬁc
human cognitive functions (ie, reading), whereas the
cognitive computing solution described in this paper is
a holistic system in which the competencies of reading,
reasoning, and learning are grouped together to
answer questions or explore novel connections.27
Some aspects of cognitive computing, such as the
ability to address data volume, velocity, variety, and
veracity, are not areas of focus in the AI development
community. Cognitive technologies are needed
because they address data challenges by applying
multiple technologies to enable comprehension of
vast, disparate data sources in a single solution.
Through a comprehensive approach to data
aggregation, comprehension, and analysis, along
with technologies that read, reason and learn, more
novel avenues in research could be discovered.Volume 38 Number 4
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is helpful to compare and contrast how human beings
and cognitive technologies engage in discovery and
various forms of decision-making processes. One way
to describe these processes is observation, interpreta-
tion, evaluation, and decision.
Observation of data is the ﬁrst step in creating a
cognitive system. It refers to the aggregation, integra-
tion, and examination of data as a foundation for
evaluation and discovery. Humans observe through
different sensory channels, such as reading relevant
publications or listening to others. Humans also often
have a pre-existing foundation of information gained
through their own observation, education, and life
experiences. These observations are retained in mem-
ory as part of a broader knowledge base.
In order to make observations, a cognitive solution
requires access to volumes of data. The identiﬁcation,
purchase, licensing, and normalization of data must
all be coordinated. With a cognitive computing sys-
tem, hundreds of external, public, licensed, and
private sources of content that may contain relevant
data are aggregated. In the case of Watson, IBM
aggregates these data into a single repository called
the Watson corpus. A unique Watson corpus is
established for each domain to which Watson is
applied. Therefore, in law, medicine, engineering,
and ﬁnance, a tailored Watson corpus could be
created with datasets and content relevant to that
domain. The content is normalized and cleansed into a
formatted dataset that can be used for analysis.
Interpretation entails the ability to understand data,
in this case, language beyond the deﬁnitions of
individual terms, to deduce the meaning of sentences
and paragraphs. As humans, we take in content and
information. We read and recognize words, trans-
lating them into abstract meaning. For example, a
chemist will recognize compounds from published
articles or patents and create a mental representation
of related compounds and the features that
deﬁne them.
Similarly, a key component of a cognitive system
entails learning the language of a speciﬁc industry or
domain. To enable language comprehension, a system
must be supplied with relevant dictionaries and
thesauri. These might include a known list of human
gene names or chemical names, but they also include
the verbs that create relationships between them such
as “express or inhibit.” Understanding the verbs,April 2016nouns, and prepositions in each sentence makes
cognitive systems different from key word search
and text analytics that may identify only the nouns
of interest or rely on matching individual words to
ﬁnd relevant information. The ability to understand
verbs, adjectives, and prepositions enables compre-
hension of what language means versus just what it
says.26
Figure 1 shows how a system like Watson is taught
how to recognize and reconcile multiple names or
synonyms for an entity into a single concept. A
cognitive system that learned about chemistry would
recognize Valium as a chemical structure. It will not
only recognize Valium, but also resolve 4100
different synonyms for Valium into a unique
chemical structure. An investigation into any
chemical will ﬁnd relevant documents that contain
different forms of that chemical’s name, not just its
brand name, for example (Figure 1). This capability is
an inherent part of a cognitive system.28,29 The
interpretation of other data formats like magnetic
resonance images, echocardiograms, or any other
visual data should be contemplated in future solution
iterations.
Like humans, a cognitive system can leverage
known vocabulary to deduce the meaning of new
terms based on contextual clues. A chemist can
recognize a newly discovered compound because it
shares attributes with other compounds that he or she
has seen before. Similarly, a cognitive system can
identify a newly approved drug by recognizing con-
textual clues like a discussion of its indication or side
effects. This learning ability is one of the greatest
differentiators between cognitive and noncognitive
technologies. In domains such as life sciences, in
which new diseases, drugs, and other biological
entities are continuously being discovered, solutions
that rely on humans to manually update their knowl-
edge base could miss important insights.
Once relevant datasets are collected and Watson
has been provided with dictionaries that enable it to
recognize terms, a set of annotators is applied to the
data. These annotators extract speciﬁc nouns and
verbs that convey relationships between proteins
(Figure 2). A chemical structure annotator will be
able to extract International Union of Pure and
Applied Chemistry or chemical names and convert
them into unique chemical structures out of the text of
scientiﬁc journal articles.29 Similarly, a gene or protein691
Sentence: “ The results show that ERK2 p53 Thr55.”phosphorylated at
Extract Entities and Types
Entity (text location) -> Entity Type: ERK2 (22,25) -> Protein; p53 (42,44)-> Protein; Thr55 (49,53)-> Amino Acid
Extract Relationships and (Agent, Verb, Object) Triplets
−Part of Speech Tags show that phosphorylated is a VERB of interest. ‘Phosphorylate’ is codified
as a Post Translational Modification relationship.
The/DT results/NNS show/VBP that/IN ERK2/NNP phosphorylated/VBD p53/NN at/IN Thr55/NNS
−Grammatical Relations to previously identified entities reveals subject/object links
nsubi(phosphorylated-6, ERK2-5); dobi(phosphorylated-6, p53-7)
−Prepositional connections indicate location property for the verb Phosphorylate
prep_at(phosphorylated-6, Thr55-9)
Result: Estracted (Agent, Verb, Object) Triplets and properties
−Agent: ERK2
−Action: phosphorylated; Base form: phosphorylate
−Object: p53
−Location : Thr55
VERB
OBJECTAGENT
LOCATION
Figure 2. Sample of Watson extracting entities. A cognitive system like Watson uses annotators which are
specialized types of computer code to read and extract terms from scientific literature. Watson
reads the sentence and recognizes nouns as proteins, verbs like phosphorylation, the object of
those verbs and the location of an event.
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Figure 1. Example of Watson concept recognition. Watson can recognize terms and many of their synonyms.
Watson can recognize a chemical such as Valium whether expressed as a chemical diagram, smile
string, chemical identification number, its generic name, and other synonyms.
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Figure 3. Watson depicting gene relationships to multiple sclerosis. This is an example of a network of genes
that Watson has produced in real time when a user types in a disease name. Watson generates
these network maps in real time, using its annotators to extract the relationships between any gene
and multiple sclerosis out of > 26 million MEDLINE abstracts.
Y. Chen et al.annotator can extract gene and protein names and
resolve gene synonyms to a single unique gene entity.
In addition to extracting individual entities such as
genes, Watson’s annotators identify the relationships
among genes, drugs, and diseases.
These annotators typically learn from patterns in
the text where they occur and then extrapolate more
generally for a given type of entity. For example, if a
gene annotator sees examples of “P53, WEE1, and
ATM” in the context of MEDLINE journal publica-
tions, it will apply machine learning and domain rules
to “ﬁgure out” other words and phrases in the text
that look like the genes IL17, IL1, and so on.30,31April 2016Deep natural language-processing and machine-
learning techniques were developed so that Watson
could teach itself about these concepts and compre-
hend the subject at a more meaningful level. Figure 3
is an example of a life sciences annotator that extracts
protein relationships from unstructured text. Figure 3
illustrates how major components of the sentence are
processed so that the protein ERK2 is recognized as
the acting agent because the next word
“phosphorylates” is recognized as a verb along with
the object of that verb, P53. Deep natural language
comprehension will also understand a preposition
such as “on” as a location with a trigger in the693
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this case, therine 55). In this speciﬁc example, the
recognition and extraction of these parts of language
enables a technology to recognize a relationship
between 2 kinases, the type of relationship, and the
location of their interaction.
When we apply domain annotators on large vol-
umes of unstructured content via the IBM Watson
technology, its processing speed extracts chemicals,
genes, and drugs from thousands of scientiﬁc pub-
lications and patents within hours. Extraction of this
information by humans would likely take signiﬁcantly
longer. The information extracted by annotators from
millions of pages of text can then be composed into a
wide variety of runtime analytics and visualizations.
Figure 2 shows 1 example of the visualizations that
one can create on top of annotated datasets.
In addition to visualizing expressed patterns, ma-
chine learning and predictive analytics generate hy-
potheses about relationships; in effect “inferring”
novel connections not yet supported by overt state-
ments in the literature as was done in a project with
Baylor College of Medicine where hypotheses of new
kinases that could phosphorylate TP53 were gener-
ated out of existing medical literature.31,32
If the observation and interpretation of concepts
are the foundation for discovery in a human’s cogni-
tive process, the next step is evaluation.30 Humans
have the ability to evaluate evidence and apply it to
solve different types of problems. Evidence can be
evaluated to provide a single best evidence-based
answer to a query or offer several answer candidates.
In the case of research, Watson evaluates evidence for
the purpose of exploration and discovery. Watson
uses evidence from text to compose visual networks of
data such as all the genes with a relationship to
Alzheimer’s disease. In this case, holistic view refers
to composing a visual depiction of all the items in a
speciﬁc group and their relationships to each other. In
the case of Watson Discovery Advisor, evidence is not
evaluated to come to a “best” answer. It is used to
discover novel relationships and new hypotheses for
further evaluation.
Once a cognitive system gains basic understanding
of domain terminology, it translates fragmented in-
formation from content into holistic pictures using
various visualizations and summarization techniques.
For example, a researcher looking for new potential
drug targets in multiple sclerosis (MS) may want to see694evidence of any genes with a relationship to that
disease. Figure 2 illustrates a network map composed
by Watson in an attempt to compose a holistic view of
the genes associated with MS. In less than a minute,
Watson processed 24 million MEDLINE abstracts and
hundreds of other pages of content and found 177
documents mentioning genes with a connection to
MS. More importantly, gene relationships are
depicted so that a user can see their relationship to
MS and to each other without having to read all 177
articles. If a user right clicks on any connecting chord
between 2 genes, the relationship between them is
summarized (ie, positive regulation) and the
researcher can access the speciﬁc passage in the
article describing the relationship. Cognitive
technologies analyze and create holistic network
maps at run time, meaning that the visualization is
created at the time that the user makes the request.
Humans would need to read each one of the 177
documents and manually draw these maps and then
update them each time new information is published.
This manual processing usually means that there is a
delay between the time that the data become available
and the time that the data are incorporated into any
solution relying on them. Cognitive systems
automatically update their visualizations when
provided with new content, which enables
researchers to leverage the most current data from
which to make new discoveries.
In the context of discovery, the term decision refers
to the ability to make a determination or take action
based on data. Such determinations may be to con-
clude that a speciﬁc protein may be a worthy new
drug target to validate in experiments. Decisions in life
sciences and medicine rely heavily on evidence. Wat-
son helps support conﬁdent decisions about where to
focus research by making evidence readily accessible
to the researcher. Further, Watson leverages quanti-
tative predictive analytics to infer relationships for
which there may not yet be explicit evidence. In this
case, Watson relies on a researcher to provide a
known set of items like genes with a relationship to
a disease. Watson uses those known genes to train
itself to identify other genes with like text traits.
Researchers then provide Watson with a candidate
list. The candidate list is a group of genes, diseases, or
drugs that a researcher would like to narrow down to
a list of high-potential options for further testing.
Watson’s ability to score a list of candidates byVolume 38 Number 4
Y. Chen et al.their text features may help researchers accelerate
their research by focusing on those Watson ranks
highest.
Presenting a Holistic View
In order to create a list of potential gene, drug, or
disease candidates that a researcher decides is worthy
of taking to experiments, he or she must ﬁrst explore
and identify novel relationships. Watson combines its
ability to observe, interpret, and evaluate with novel
data representation approaches. Two of the more
novel approaches include presenting information in
holistic relationship maps and promoting cross-
domain linking. Holistic relationship maps are visual
networks of relationships that help researchers see a
full depiction of a group of drugs, diseases, and genes
and their connections. Cross-domain linking refers to
leveraging data across all therapeutic areas, study
types, and disciplines to inform those novel connec-
tions or hypotheses.
As discussed previously, much of the data gener-
ated and collected both publicly and privately about a
given drug are kept in silos. As a result, what might
have been learned during different phases of develop-
ment is often isolated from other insights. Addition-
ally, the tools used to analyze these data are often
speciﬁcally designed for use at particular phases of
drug development such as mass spectrometry for
protein identiﬁcation. During drug design, develop-
ment, and clinical research, different groups of re-
searchers each use unique data types and analytical
tools to understand data that are maintained speciﬁ-
cally for their type of research. Cognitive solutions
enable the integration of these data to combine
discoveries made across the drug’s development life
cycle. Watson then creates a holistic visualization out
of all the data in simple formats such as network
maps, depicting more relationships and a fuller view
of the information available.
From Serendipity to Intention: Making
Cross-Domain Linkages a Core Feature Discovery
Harnessing big data and presenting them in holistic
visualizations can encourage the identiﬁcation of
novel connections that would otherwise have only
been made by chance. Science and medicine have
experienced leaps forward through fortuitous discov-
eries. Well-known examples include penicillin, cispla-
tin, warfarin, and the smallpox vaccine.33–35April 2016Serendipity has been attributed to up to 24% of all
discovered drugs.34,35 Often the discovery emerged
from connections made when seemingly dissimilar
domains were brought together by chance. For exam-
ple, an observation that people resistant to the small-
pox disease were often dairy farmers in close contact
with infected cattle eventually led to the creation of an
effective vaccine for humans.33
Cognitive computing technologies can be conﬁg-
ured to make cross-domain linkages versus rely on
serendipity. For example, insights about a gene
entity such as its role or function can be derived
from many sources. A cancer researcher seeking to
discover the role of a given gene in cancer may miss
insights if the search is limited to the literature
related to that disease. A cognitive discovery plat-
form will surface all information about a given entity
regardless of the disease, journal, or even species
of study.
Another way in which cognitive discovery uses
cross-domain linkages is demonstrated in drug repur-
posing. Big data could be useful in drug repurposing
because information about drugs, their mechanisms of
action, targets, effects, and outcomes could be used to
inform development of new therapies. The challenge is
that data about drugs are kept in a variety of
repositories such as the animal study results from
preclinical studies, clinical trial data generated from
Phase I through III clinical trials, the labels of all
approved therapies, and the adverse event reports kept
in drug safety databases. In this case, Watson can be
used to look across all of this information, exploring
all drugs for mechanism-of-action similarity or across
all diseases for shared pathways such as an inﬂam-
matory pathway or an immunological pathway.
A drug label, animal study, in vitro cell experiment
results, and human trials combined may reveal a novel
relationship that could help unlock a new indication.
One of the “test” cases for Watson Discovery Advisor
discussed later in this article further discusses the use
of Watson for drug repurposing in the treatment of
malaria.PART IV: HOW WATSON DISCOVERY
ADVISOR COULD AID LIFE SCIENCES
RESEARCH
Figure 4 illustrates the basic architecture for Watson
as it has been applied to the life sciences domain. The695
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Figure 4. Watson Discovery Advisor applied to Life Sciences. This is a depiction of the architecture Watson
leverages when being applied to the life sciences domain including the aggregation of data, the
recognition of major scientific concepts and then an interface that enables a researcher to explore.
Clinical Therapeuticsﬁgure illustrates the layers that comprise a cognitive
solution starting with the content and data sources
that are relied on by researchers. In addition to these
data, Watson is trained to recognize and understand
the key concepts such as recognizing genes and the
role they play or drugs and their relationships to
indications and side effects. The top layer is the
dynamic user interface that surfaces graphics like
bars showing posttranslational modiﬁcations on the
sites of a protein, for example, or a group of articles
retrieved in response to a query. As shown in
Figure 4, the foundation of a cognitive system
involves aggregating different data types. By
aggregating big datasets, Watson is then in a
position to ﬁnd connections between them.
Researchers are challenged to replicate this output
because they often cannot gain access to such
volumes of data and lack technologies to pull the
data together and ﬁnd the meaningful connections.
Today, there are some tools that attempt to do this,
but the data are often manually searched, reviewed,
and mapped by humans, which limits the amount of
data and number of sources that can be leveraged.
There are also limits to the speed at which the data
can be evaluated and that introduce human bias into
the discovery process. In life sciences, examples of696the relevant data types include published literature,
patents, preclinical animal study reports, clinical trial
data, genomic information, drug labels, and
pharmacology data. Some data can be accessed
from public domain or third-party content providers.
Other content might be owned by private enter-
prises. Some data will come in structured data
formats such as chemical structures, whereas others
might be unstructured, such as published journal
articles. A solution should be built to ingest and link
such datasets in a secure, coherent, and scalable
fashion and anticipate continuous creation of new
data, new data formats, and emergence of new data
types.
Today, Watson Discovery Advisor for Life Sciences
is supplied with dictionaries, thesauri, and ontologies
on genes, proteins, drugs, and diseases. It includes
annotators that are tested for accuracy in recognizing,
extracting, and categorizing these entities. Last, the
data are surfaced for evaluation via network maps, co-
occurrence tables, and other visualizations that pro-
mote insight. These visualizations along with a
question-and-answer function allow researchers to
seek evidence-supported answers to a question or
explore any relationship for which any level of
evidence exists.Volume 38 Number 4
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IBM Watson was originally a research experiment
to determine whether a computer could be taught to
read volumes of text such as Wikipedia, newspapers,
and other text-based sources of information and
produce reliable evidence-driven answers in response
to natural language questions. The project culminated
in a public demonstration of the technology on the
game show Jeopardy in 2011 during which Watson
defeated 2 human Jeopardy champions. Shortly there-
after, several organizations from different industries
approached IBM to understand where Watson could
be adapted to speciﬁc business challenges. Baylor
College of Medicine was one such group. Watson
Discovery Advisor has been applied in several pilot
projects. Two of them described here include a study
of kinases in cancer and repurposing of drug com-
pounds for potential treatment of malaria.
Test Case 1: Baylor College of Medicine:
A Retrospective and Prospective Exploration of
Kinases
In 2013, Baylor College of Medicine approached
IBM to understand whether Watson Discovery Advi-
sor could enhance insight into cancer kinases. The
research project included a retrospective and prospec-
tive exercise exploring kinase relationships.
Research Question
The research challenge was whether Watson could
predict kinases that might phosphorylate the P53
protein. In order to evaluate Watson’s predictive
abilities, a study had to be designed in which Watson
used information from the past to identify kinase
relationships that were later validated and published.
For the pilot, Watson was trained on kinases that had
been observed to phosphorylate P53 using evidence in
published literature through the year 2002. Watson
then used this training and the MEDLINE abstracts
through 2002 to “guess at” the kinases discovered to
phosphorylate P53 in the following decade spanning
2003 to 2013.31
Study Design
In designing the retrospective experiment, Watson
was provided a set of human kinases known to
phosphorylate P53. Using text mining, Watson read
all the articles discussing the known kinases provided
to IBM. With text feature analysis and graph-basedApril 2016diffusion, Watson found and visualized text similarity
patterns between these kinases. Once these models
were reﬁned, they were applied to the MEDLINE
abstracts up through 2002 to determine whether
Watson could identify the kinases discovered in the
period 2003 to 2013. Figure 5 illustrates how the
kinase relationships were mapped based on their
literature distance. The kinases whose text patterns
were most similar to a set of kinases already known to
phosphorylate P53 suggested that they had highest
likelihood of also phosphorylating P53.31RESULTS
The results of the study were that over the course of
several weeks, IBM researchers using Watson tech-
nology identiﬁed 9 potential kinases that would
phosphorylate P53. Of these, Baylor validated that 7
had in fact been discovered and validated through
published experiments during the following decade
from 2003 to 2013.31 These results suggested that
cognitive computing on large unstructured datasets
could accelerate discovery of relationships between
biological entities for which there was yet no explicit
evidence of their existence.
Watson was then applied in a prospective explora-
tion of the full set of MEDLINE abstracts through
2013. Watson surfaced a ranked set of additional
kinases with various levels of probability of phosphor-
ylating P53. PKN1 and NEK1 were 2 kinases highly
ranked by Watson as having the potential to phos-
phorylate P53.32 Lab experiments at Baylor College of
Medicine suggested that these kinases could phos-
phorylate P53 in both in vitro experiments and in tests
on human cells. Further experiments are being
conducted to test the activity of these kinases in
organisms. The results of the retrospective study
were published in the 20th Association for Com-
puting Machinery (ACM) Society for Knowledge
Discovery in Data SKDD international conference
proceedings held in August 2014.31 The prospective
Watson study identifying PNK1 and NEK1 was
published in August 2015.32
Test Case 2: Applying Watson to Drug
Repurposing
Cross-domain discovery, the detection of a new
insight or relationship based on information from 2 or
more domains, was demonstrated in a pilot project with697
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Figure 5. High-potential cancer kinase network. This is the result of Watson performing text analytics on
kinases known to phosphorylate PT53 and a group of proteins that were tested to evaluate their
potential to phosphorylate TP53.
Clinical Therapeuticsa large biopharmaceutical company. In this case, the
project objective was to identify compounds in the
company’s existing therapeutic portfolio with the poten-
tial to treat of malaria. The study method included
exploration of MEDLINE literature looking across all
drugs approved for use in humans. Watson then
searched for statements suggesting efﬁcacy against the
malaria parasite. The second part of the study method
looked at all of the company’s existing compounds and
identiﬁed any that had a structural similarity to known
malaria treatments by looking for similarity in chemical
structure and mechanism of action.
The result of this proof-of-concept project was that
15 drug candidates from the company’s existing portfo-
lio were identiﬁed for further study.36 The actual
duration of the exploration using Watson technology698took less than 1 month. The company had been working
on this endeavor with at least 10 research scientists over
14 months and had found a similar number of
candidates. Between the 2 lists of candidates generated
by the pharmaceutical company and Watson, about half
of them were the same. The other half of candidates on
the list produced by Watson were candidates that the
company researchers had not identiﬁed during the
course of their research. The company chose to take
the results internally, and further study of the candidates
was never disclosed.
PART V: THE FUTURE OF COGNITIVE
DISCOVERY
Early pilot research projects with Watson in cancer
kinase research and drug repurposing suggest that theVolume 38 Number 4
Y. Chen et al.attributes of a cognitive system could potentially aid
researchers in making connections out of large data-
sets faster than and potentially aid them in making
connections that they may not have otherwise consid-
ered.31,32,36 To determine where cognitive systems
might add the most value, Watson should be applied
to a breadth of research questions. Although Watson
has been applied to research on cancer kinases and
drug repurposing, other projects such as predicting
combinations of genes or proteins that as a group may
play a role in disease onset or progression should also
be attempted. The projects should cover a breadth of
entities from biomarkers to biological processes to
biologics and should cover several therapeutic areas to
determine whether the predictive models can be used
across disease states. Exercises using various data
types will also yield important information about
whether predictive models can be further enhanced
by combining structured and unstructured data to
unlock novel insights. If Watson can be successfully
trained on a breadth of entity types across disease
states, it could help accelerate discoveries about
disease origins, contributing pathways and novel drug
targets.
Additionally, the current capability of Watson to
read and extract relationships from text is being
applied to pilot research projects in pharmacovigi-
lance. A few research projects with large pharmaceut-
ical companies have involved the application of
Watson to reading both published journal articles
and adverse event case reports to evaluate whether
Watson can assist the drug safety process through
faster recognition and coding of adverse events out of
text. In this case, Watson may be used to augment
existing drug safety personnel to speed their work and
support timely reporting of adverse events to US and
European regulatory agencies.
CONCLUSIONS
Cognitive computing solutions patterned after several
key aspects of human thought are emerging in many
industries. Their ability to ingest varieties of data and
to understand, evaluate, and learn from the data has
the potential to unlock novel insights. These solutions
may enhance areas such as Life Sciences, which are in
dire need of accelerated innovation. Early pilot proj-
ects discussed here suggest that cognitive computing
infuses novelty and adds speed to the research process.
Further study is needed to validate its utility inApril 2016different therapeutic areas and research domains.
Cognitive computing may also add value in the
identiﬁcation and coding of adverse event reports
from the text of case reports and published articles.
Current pilot projects are beginning to yield insight
into whether Watson has the potential to improve
both the accuracy and speed of adverse-event detec-
tion and coding. As with discovery, multiple test cases
across event types, drug types, and diseases will be
needed to evaluate and improve Watson’s abilities in
drug safety. In both cases, IBM will learn from each
engagement and improve Watson’s ability to both
extract known relationships and hypothesize novel
relationships through predictive text analytics.ACKNOWLEDGMENTS
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